The prostate theranostics market is expanding fast. Novartis reported Pluvicto Q2 2026 sales up c. 43% yoy. Stronger therapy volumes relate to more Ga-68 PSMA PET diagnostics, often utilizing EUZ's Ga-68 generator. EUZ is benefitting from the demand, currently accounting for an estimated 60-80% of the Ga-68 generator market with its product GalliaPharm (c. 20% of group revenues).
LÄS MER